Daniel Scolnick

Daniel Scolnick

Pepper Hamilton LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

More Biotech and Diagnostic Patents At Risk After Federal Circuit Decision

On December 17, 2014, the Federal Circuit Court of Appeals found that certain claims relating to Myriad’s BRCA1 genetic test for breast and ovarian cancer were invalid under 35 U.S.C. § 101 as being ineligible for patent...more

12/19/2014 - AMP v Myriad Biotechnology CLS Bank v Alice Corp DNA Mayo v. Prometheus Patent-Eligible Subject Matter Patents Section 101

FDA’s 'Purple Book' for Biologics—Patents Not Included

This past week, the Food and Drug Administration (FDA) announced the creation of the “Purple Book,” which will list all biological products, including any biosimilar and interchangeable biological products, licensed by the...more

9/16/2014 - Biologics FDA Pharmaceutical Patents Purple Book

Federal Circuit Clarifies Patent Term Adjustment Provisions

On January 15, 2014, the Federal Circuit issued in Novartis v. Lee its anticipated opinion regarding the proper interpretation of 35 U.S.C. § 154, the statute that determines how patent term adjustment (PTA) is calculated....more

1/16/2014 - Patent Litigation Patent Reform Patent Term Adjustment Patent Terms Patents USPTO

Human Genes Are Not Patent Eligible Subject Matter

Today, the U.S. Supreme Court held that human genes are not patent eligible subject matter under 35 U.S.C. §101 simply because they have been isolated from the surrounding genetic material....more

6/14/2013 - AMP v Myriad DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS

Paying Your Dues ... Your Maintenance Fees Will Become Significantly More Expensive

The United States Patent and Trademark Office (USPTO) has recently published increases in maintenance fees that are effective on March 19, 2013. Careful attention to your maintenance fee schedule may provide a savings for...more

2/12/2013 - Maintenance Fees Patents USPTO

5 Results
|
View per page
Page: of 1